Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer

AIM: To evaluate the dosimetry, efficacy and toxicity of intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy for patients with locally advanced cervical and upper thoracic esophageal cancer. METHODS: A retrospective study was performed on 7 patients who were definitively treated...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 12; no. 34; pp. 5501 - 5508
Main Authors Wang, Shu-Lian, Liao, Zhongxing, Liu, Helen, Ajani, Jaffer, Swisher, Stephen, Cox, James D, Komaki, Ritsuko
Format Journal Article
LanguageEnglish
Published United States Department of Radiation Oncology, Cancer Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China%Department of Radiation Oncology, the University of Texas M D Anderson Cancer Center, United States%Department of Gastrointestinal Medical Oncology, the University of Texas M D Anderson Cancer Center,United States%Department of Cardiovascular and Thoracic Surgical Oncology, the University of Texas M D Anderson Cancer Center, United States 14.09.2006
Baishideng Publishing Group Co., Limited
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:AIM: To evaluate the dosimetry, efficacy and toxicity of intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy for patients with locally advanced cervical and upper thoracic esophageal cancer. METHODS: A retrospective study was performed on 7 patients who were definitively treated with IMRT and concurrent chemotherapy. Patients who did not receive IMRT radiation and concurrent chemotherapy were not included in this analysis. IMRT plans were evaluated to assess the tumor coverage and normal tissue avoidance. Treatment response was evaluated and toxicities were assessed. RESULTS: Five- to nine-beam IMRT were used to deliver a total dose of 59.4-66 Gy (median: 64.8 Gy) to the primary tumor with 6-MV photons. The minimum dose received by the planning tumor volume (PTV) of the gross tumor volume boost was 91.2%-98.2% of the prescription dose (standard deviation [SD]: 3.7%-5.7%). The minimum dose received by the PTV Of the clinical tumor volume was 93.8%-104.8% (SD: 4.3%-11.1%) of the prescribed dose. With a median follow-up of 15 rno (range: 3-21 too), all 6 evaluable patients achieved complete response. Of them, 2 developed local recurrences and 2 had distant metastases, 3 survived with no evidence of disease. After treatment, 2 patients developed esophageal stricture requiring frequent dilation and 1 patient developed tracheal-esophageal fistula. CONCLUSION: Concurrent IMRT and chemotherapy resulted in an excellent early response in patients with locally advanced cervical and upper thoracic esophageal cancer. However, local and distant recurrence and toxicity remain to be a problem. Innovative approaches are needed to improve the outcome.
Bibliography:Intensity-modulated radiation therapy
R735
Chemotherapy
14-1219/R
Esophageal cancer; Intensity-modulated radiation therapy; Chemotherapy
Esophageal cancer
Telephone: +1-713-56302300 Fax: +1-713-5632366
Correspondence to: Zhongxing Liao, MD, Department of Radiation Oncology, the University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, United States. zliao@mdanderson.org
ISSN:1007-9327
2219-2840
DOI:10.3748/wjg.v12.i34.5501